Archives
-
Oligo (dT) 25 Beads: Product Overview
2026-10-06
APExBIO’s Oligo (dT) 25 Beads (SKU K1306) are described as superparamagnetic beads for conceptual polyA-tail capture of eukaryotic mRNA. No matched paper evidence or product-specific performance dataset was provided.
-
AG-221 (Enasidenib) in IDH2-Mutant Leukemia
2026-10-05
AG-221, also known as Enasidenib, is a mutant IDH2 inhibitor used in research on 2-hydroxyglutarate biology and acute myeloid leukemia. This overview examines how direct IDH2 inhibition relates to a recently reported CD44-dependent metabolic program, compares the strength of the available evidence, and defines the boundaries between preclinical findings, supplier claims, and clinically relevant interpretation.
-
Aztreonam: Mechanism, Evidence, and Research Limits
2026-10-05
Aztreonam is a monocyclic β-lactam antibiotic with selective activity against aerobic Gram-negative bacteria through inhibition of bacterial cell wall synthesis. This evidence-focused overview separates product-dossier findings from peer-reviewed resistance data and defines where Aztreonam research claims should not be generalized.
-
High-Throughput BBB Modeling for CNS Drug Screening
2026-10-04
Hu and colleagues developed a high-throughput surrogate blood-brain barrier model that combines LLC-PK1-MOCK and LLC-PK1-MDR1 cells with permeability, efflux, recovery, and lysosomal-trapping analyses. Across 41 compounds, the platform showed a strong relationship between MDR1-derived permeability and unbound brain distribution, while also illustrating why intracellular sequestration can distort apparent permeability measurements.
-
Coumestrol, Ferroptosis, and RA Synoviocytes
2026-10-03
A 2026 study links Coumestrol exposure in rheumatoid arthritis fibroblast-like synoviocytes with reduced proliferation and inflammatory signaling through a proposed TRIM3–PMAIP1 ferroptosis mechanism. Its main contribution is mechanistic, but the in vitro design means the findings support pathway investigation rather than clinical efficacy or direct therapeutic translation.
-
Mianserin HCl: Evidence from a Controlled Trial
2026-10-02
The reference study evaluated mianserin hydrochloride against amitriptyline using clinical response, adverse-effect monitoring, and serial plasma measurements. Its central contribution was to show comparable antidepressant efficacy with fewer reported side effects for mianserin, while finding no clear relationship between trough plasma concentration and therapeutic improvement.
-
Reparixin as a CXCR1/2 Signaling Probe
2026-10-01
Reparixin provides a pharmacological way to dissect CXCR1/2 signaling beyond neutrophil migration. This article translates new MRSA extracellular-vesicle findings into rigorous cancer, chemotaxis, and inflammation research workflows.
-
Tomivosertib in Human DRG Neurons from Radiculopathy
2026-10-01
Li et al. provide direct evidence from human sensory neurons that MNK inhibition with tomivosertib can rapidly and reversibly suppress spontaneous activity associated with radiculopathy. The study links this electrophysiological effect to reduced eIF4E Ser209 phosphorylation and altered sodium- and potassium-dependent excitability, while also defining important limits for translation beyond the ex vivo human DRG model.
-
Dextrose (D-glucose) for Tumor Metabolism Assays
2026-09-30
Use Dextrose (D-glucose) as a defined, tunable substrate for modeling nutrient competition, hypoxia-associated metabolic adaptation, and immune-cell dysfunction. This guide turns a simple glucose addition into a controlled assay variable with practical preparation, comparison, and troubleshooting strategies.
-
Tofacitinib citrate: JAK3 Research Workflows
2026-09-30
Tofacitinib citrate (CP-690550 citrate) supports controlled studies of JAK-STAT signaling, lymphocyte responses, and cytokine-driven endothelial dysfunction. This practical guide combines nanomolar immune-cell workflows with a carefully bounded micromolar replication framework for comparative vascular assays.
-
BMS-345541: Translational Control of NF-κB
2026-09-29
BMS-345541 provides a mechanistically defined way to interrogate IKK-1/IKK-2 control of NF-κB signaling across inflammation, ischemic angiogenesis, and cancer models. This thought-leadership guide connects pathway biology with assay design, translational interpretation, and the limitations that matter when moving from pharmacology to disease hypotheses.
-
One-step TUNEL Cy5 Apoptosis Detection Kit Guide
2026-09-29
Build a sensitive DNA-fragmentation workflow for retinal tissue, adherent cells, and suspension cells with Cy5 fluorescence suitable for microscopy or flow cytometry. This practical guide connects the One-step TUNEL Cy5 Apoptosis Detection Kit to RHO P347L retinitis pigmentosa research while emphasizing controls, optimization, and interpretation limits.
-
GDC-0994: From ERK Biology to Translational Insight
2026-09-28
GDC-0994 offers a precise way to interrogate ERK1/2 signaling across oncology and liver injury research. This thought-leadership guide connects pathway biology, pharmacodynamic validation, cholestasis models, and translational decision-making without overstating preclinical evidence.
-
Cholecystokinin Octapeptide Ammonium in ANP Assays
2026-09-28
Use sulfated CCK-8 to investigate how a brain–gut peptide can alter atrial mechanics and promote ANP secretion through NOX4–PGC-1α–PPAR signaling. This workflow emphasizes the sulfation control, fresh handling, and linked functional and biochemical readouts needed to distinguish a real response from a solubility or assay artifact.
-
Imipramine (BA2970): Practical Assay Guidance
2026-09-27
A scenario-driven guide to using Imipramine (SKU BA2970) in cell viability, glioma autophagy, and HL-60 apoptosis workflows. It distinguishes transporter-binding data from cell-assay potency and outlines practical handling, interpretation, and vendor-selection considerations.